Sean D Sullivan

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan
    Sean D Sullivan
    University of Washington, Seattle, Washington 98195, USA
    J Gastroenterol Hepatol 22:1494-9. 2007
  2. doi request reprint An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma
    S D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Allergy 63:670-84. 2008
  3. ncbi request reprint A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Pharmacotherapy 29:1280-8. 2009
  4. doi request reprint The impact of diabetes counseling and education: clinical and cost outcomes from a large population of US managed care patients with type 2 diabetes
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, Seattle, WA 98195 7630, USA
    Diabetes Educ 39:523-31. 2013
  5. doi request reprint Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    J Med Econ 16:391-6. 2013
  6. doi request reprint Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score
    Sean D Sullivan
    University of Washington, Seattle, WA 98195 7630, USA
    J Med Econ 14:609-16. 2011
  7. pmc Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
    Sean D Sullivan
    Pharmaceutical, Outcomes Research and Policy Program, University of Washington, Seattle, USA
    Cardiovasc Diabetol 8:12. 2009
  8. ncbi request reprint Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Value Health 9:68-76. 2006
  9. ncbi request reprint Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle 98195 7630, USA
    Pharmacoeconomics 21:477-96. 2003
  10. ncbi request reprint Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C
    Sean D Sullivan
    University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 22:257-65. 2004

Detail Information

Publications133 found, 100 shown here

  1. ncbi request reprint Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan
    Sean D Sullivan
    University of Washington, Seattle, Washington 98195, USA
    J Gastroenterol Hepatol 22:1494-9. 2007
    ....
  2. doi request reprint An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma
    S D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Allergy 63:670-84. 2008
    ..In patients who respond to therapy, the cost-effectiveness of omalizumab compares well with other biologic treatments for chronic illness...
  3. ncbi request reprint A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Pharmacotherapy 29:1280-8. 2009
    ..To project and compare long-term outcomes of morbidity and mortality, and costs of complications of type 2 diabetes mellitus from a randomized controlled trial of patients receiving liraglutide versus glimepiride monotherapy...
  4. doi request reprint The impact of diabetes counseling and education: clinical and cost outcomes from a large population of US managed care patients with type 2 diabetes
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, Seattle, WA 98195 7630, USA
    Diabetes Educ 39:523-31. 2013
    ..The purpose of this study is to examine outcomes in adult patients with type 2 diabetes mellitus who received diabetes counseling and education (C/E) services compared with those who did not...
  5. doi request reprint Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    J Med Econ 16:391-6. 2013
    ..However, little is known about whether or not switching to anti-TNF or other non-TNF biologic treatments is cost-effective. This study sought to review the economic evidence of sequencing various biologic treatments in RA...
  6. doi request reprint Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score
    Sean D Sullivan
    University of Washington, Seattle, WA 98195 7630, USA
    J Med Econ 14:609-16. 2011
    ..The first approach identified high risk patients using impaired fasting glucose (IFG). The second approach used the PreDx Diabetes Risk Score (DRS) to further stratify IFG patients into high-risk and moderate-risk groups...
  7. pmc Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
    Sean D Sullivan
    Pharmaceutical, Outcomes Research and Policy Program, University of Washington, Seattle, USA
    Cardiovasc Diabetol 8:12. 2009
    ..Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepiride...
  8. ncbi request reprint Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Value Health 9:68-76. 2006
    ..To evaluate the cost-effectiveness of fondaparinux relative to enoxaparin as prophylaxis against venous thromboembolism (VTE) in patients undergoing hip fracture surgery...
  9. ncbi request reprint Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle 98195 7630, USA
    Pharmacoeconomics 21:477-96. 2003
    ..These recommendations are based on extensive examination of recent advances in the management of VTE combined with a greater understanding of its natural history...
  10. ncbi request reprint Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C
    Sean D Sullivan
    University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 22:257-65. 2004
    ..The objective of this study was to determine if the gain in SVR with peginterferon alpha-2a plus ribavirin is worth the incremental cost...
  11. ncbi request reprint The promise of specialty pharmaceuticals: are they worth the price?
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    J Manag Care Pharm 14:S3-6. 2008
    ..Due in part to the cost of these therapies, payers are increasingly demanding evidence of their value. Determining the value of these medications is hampered by a lack of robust pharmacoeconomic data...
  12. ncbi request reprint Exploring new frontiers in asthma management for optimal therapeutic and economic outcomes
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, 1959 NE Pacific Ave, Box 357630, Seattle, WA 98195, USA
    J Manag Care Pharm 9:2. 2003
  13. ncbi request reprint A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery
    Sean D Sullivan
    Department of Pharmacy and Health Services, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 22:605-20. 2004
    ..To determine the cost effectiveness of fondaparinux sodium compared with enoxaparin sodium for prophylaxis against venous thromboembolism in patients undergoing major orthopaedic surgery...
  14. ncbi request reprint The economic burden of COPD
    S D Sullivan
    Departments of Pharmacy and Health Services, University of Washington, Seattle, WA 98195, USA
    Chest 117:5S-9S. 2000
    ..These trends reflect population aging, smoking patterns, institutional factors, and treatment practices...
  15. ncbi request reprint Health state preference assessment in diabetic peripheral neuropathy
    Sean D Sullivan
    Department of Pharmacy, University of Washington, Seattle, Washington 98195 7630, USA
    Pharmacoeconomics 20:1079-89. 2002
    ..To assess patient preferences for health states associated with diabetic peripheral neuropathy (DPN)...
  16. ncbi request reprint Asthma in the United States: recent trends and current status
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, 1959 NE Pacific Ave, Box 357630, Seattle, WA 98195, USA
    J Manag Care Pharm 9:3-7. 2003
    ....
  17. ncbi request reprint A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II)
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program and Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
    Arch Pediatr Adolesc Med 159:428-34. 2005
    ....
  18. ncbi request reprint Emerging therapeutic strategies for asthma management
    Sean D Sullivan
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, 1959 NE Pacific Ave, Box 357630, Seattle, WA 98195, USA
    J Manag Care Pharm 9:14-21. 2003
    ..The describe the mechanisms of action of and clinical experience to date with novel asthma drug therapies...
  19. pmc Study protocol: the Back Pain Outcomes using Longitudinal Data (BOLD) registry
    Jeffrey G Jarvik
    Department of Radiology, University of Washington, Seattle, WA, USA
    BMC Musculoskelet Disord 13:64. 2012
    ....
  20. ncbi request reprint Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom
    David L Veenstra
    University of Washington, Seattle, Washington 98195, USA
    Eur J Gastroenterol Hepatol 19:631-8. 2007
    ..We assessed the clinical outcomes and costs, from the perspective of the UK National Health Service, of 48 weeks of peginterferon alpha-2a (40 kDa) vs. 4 years of lamivudine...
  21. doi request reprint HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan
    David L Veenstra
    University of Washington, Seattle, WA, USA
    Value Health 11:131-8. 2008
    ..Our objective is to evaluate the incremental cost-effectiveness of 48 weeks of peginterferon alfa-2a compared to 48 weeks of lamivudine, from the perspective of the Taiwan Bureau of National Health Insurance...
  22. ncbi request reprint A multisite randomized trial of the effects of physician education and organizational change in chronic-asthma care: health outcomes of the Pediatric Asthma Care Patient Outcomes Research Team II Study
    Paula Lozano
    Center for Health Studies, Group Health Cooperative, 1730 Minor Avenue, Seattle, WA 98101, USA
    Arch Pediatr Adolesc Med 158:875-83. 2004
    ..Traditional primary care practice change approaches have not led to full implementation of national asthma guidelines...
  23. pmc Study protocol- Lumbar Epidural steroid injections for Spinal Stenosis (LESS): a double-blind randomized controlled trial of epidural steroid injections for lumbar spinal stenosis among older adults
    Janna L Friedly
    Comparative Effectiveness, Cost and Outcomes Research Center, University of Washington, Seattle, USA
    BMC Musculoskelet Disord 13:48. 2012
    ....
  24. ncbi request reprint Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 25:963-77. 2007
    ..Previous economic analyses have been limited by the lack of comparative clinical data for entecavir and lamivudine beyond 1-year duration and for salvage therapy...
  25. pmc An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis
    Josh J Carlson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Washington 98195, USA
    J Gastroenterol Hepatol 24:786-91. 2009
    ..To assess the clinical and economic outcomes of non-invasive testing strategies in the diagnosis of significant liver fibrosis (Metavir score >or= 2) compared with liver biopsy...
  26. ncbi request reprint Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state
    Vincent W Lin
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington
    Surg Obes Relat Dis 9:701-5. 2013
    ..Our objective was to estimate the amount of postoperative weight loss, change in co-morbidity status, and complications after LAGB. The setting was LAGB surgical centers in Washington state...
  27. doi request reprint BMI trajectories among the severely obese: results from an electronic medical record population
    Edwin S Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Obesity (Silver Spring) 20:2107-12. 2012
    ..Our results also suggest that once the 35 BMI threshold is reached, individuals will continue to remain severely obese, especially at younger ages...
  28. pmc Electronic prescribing at the point of care: a time-motion study in the primary care setting
    Emily Beth Devine
    Biomedical and Health Informatics, School of Medicine, University of Washington, Seattle, WA
    Health Serv Res 45:152-71. 2010
    ..Two primary aims were to compare prescribing time between (1) handwritten and electronic (e-) prescriptions and (2) e-prescriptions using differing hardware configurations...
  29. doi request reprint Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy
    Scott D Ramsey
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center and University of Washington Department of Medicine, Seattle, WA 98109, USA
    Value Health 12:217-25. 2009
    ....
  30. ncbi request reprint The cost-effectiveness of the management of acute sinusitis
    Yoshimi Anzai
    Department of Radiology, University of Washington, Seattle 98195 7115, USA
    Am J Rhinol 21:444-51. 2007
    ..Sinusitis is a common medical disease with a tremendous economic impact on health care. Our objective was to determine the most cost-effective strategy for the management of acute sinusitis from the societal and payers' perspectives...
  31. pmc Quality of life in adolescents with mild asthma
    Teal S Hallstrand
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, Washington 98195 6522, USA
    Pediatr Pulmonol 36:536-43. 2003
    ..Symptoms of dyspnea during exercise are common in asthma and are associated with lower HRQoL. The clinical significance of these differences in HRQoL is unclear...
  32. ncbi request reprint The economics of venous thromboembolism prophylaxis: a primer for clinicians
    Bruce L Davidson
    Pulmonary and Critical Care Medicine Division, Swedish Medical Center and University of Washington School of Medicine, 801 Broadway, Suite 915, Seattle, WA 98122, USA
    Chest 124:393S-396S. 2003
    ..It is possible to list the important safety and efficacy outcomes of prophylaxis, estimate their incidences and costs, and "model" comparisons of one modality vs another, in order to help decide whether one is preferable...
  33. ncbi request reprint Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply
    Brian Custer
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, USA
    Med Decis Making 25:571-82. 2005
    ..However, as a result of increasingly stringent screening measures, one of the greatest threats may be an insufficient supply. The balance between safety and adequacy of the blood supply has not received enough attention...
  34. doi request reprint The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision
    David R Flum
    University of Washington Schools of Medicine, Pharmacy and Public Health, Seattle, WA, USA
    Ann Surg 254:860-5. 2011
    ..To determine the impact of the Centers for Medicare and Medicaid Services' (CMS) bariatric surgery national coverage decision (NCD) on the use, safety, and cost of care CMS beneficiaries...
  35. doi request reprint Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy
    Jeannine S McCune
    Department of Pharmacy, University of Washington, Seattle, USA
    Pharmacotherapy 32:7-19. 2012
    ....
  36. ncbi request reprint Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care
    Kam L Capoccia
    Departments of Pharmacy and Family Medicine, University of Washington, Seattle, USA
    Am J Health Syst Pharm 61:364-72. 2004
    ..The impact of pharmacist interventions on the care and outcomes of patients with depression in a primary care setting was evaluated...
  37. doi request reprint Health care use and primary prophylaxis with colony-stimulating factors
    Sean D Sullivan
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Value Health 14:247-52. 2011
    ..We examined health care use in conjunction with primary prophylaxis use of colony stimulating factors (CSF) during patients' initial course of chemotherapy...
  38. ncbi request reprint Conventional radiography, rapid MR imaging, and conventional MR imaging for low back pain: activity-based costs and reimbursement
    Darryl T Gray
    Department of Pediatrics, School of Medicine, University of Washington, 146 N Canal St, Suite 300, Seattle, WA 98103, USA
    Radiology 227:669-80. 2003
    ..To incorporate personnel and equipment use time in an activity-based cost comparison of conventional radiography and conventional and rapid magnetic resonance (MR) imaging for low back pain (LBP)...
  39. ncbi request reprint The impact of accreditation on safety and cost of bariatric surgery
    Steve Kwon
    Surgical Outcomes Research Center in the Department of Surgery and the Department of Health Services, University of Washington, Seattle, Washington
    Surg Obes Relat Dis 9:617-22. 2013
    ..We used inpatient care data of those with employer-sponsored insurance plans across United States using the MarketScan Commercial Claims and Encounter Database (2003-2009)...
  40. doi request reprint Bioequivalent antiepileptic drug switching and the risk of seizure-related events
    Ryan N Hansen
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, United States
    Epilepsy Res 106:237-43. 2013
    ..We investigated the association between A-rated switching of each class of currently available AED and emergent treatment for a seizure-related event...
  41. doi request reprint Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach
    Vincent W Lin
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Value Health 16:823-9. 2013
    ..To estimate the relationship between health utilities and body mass index (BMI) among a cohort of obese patients who underwent laparoscopic adjustable gastric banding (LAGB)...
  42. ncbi request reprint Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial
    Jeffrey G Jarvik
    Department of Radiology, University of Washington, Seattle, Wash 98195, USA
    JAMA 289:2810-8. 2003
    ..However, whether rapid MRI scanning results in better patient outcomes than radiographic evaluation or a cost-effective alternative is unknown...
  43. pmc Examining the BMI-mortality relationship using fractional polynomials
    Edwin S Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    BMC Med Res Methodol 11:175. 2011
    ..This approach was then compared against other commonly used regression models...
  44. doi request reprint A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Med Care 46:542-8. 2008
    ....
  45. doi request reprint Expenditures and health status among adults with back and neck problems
    Brook I Martin
    Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, WA 98104, USA
    JAMA 299:656-64. 2008
    ..Back and neck problems are among the symptoms most commonly encountered in clinical practice. However, few studies have examined national trends in expenditures for back and neck problems or related these trends to health status measures...
  46. ncbi request reprint A systematic review to assess comparative effectiveness studies in epidural steroid injections for lumbar spinal stenosis and to estimate reimbursement amounts
    Brian W Bresnahan
    Department of Radiology, University of Washington, Seattle, WA 98104 2499, USA
    PM R 5:705-14. 2013
    ..TYPE: Systematic review...
  47. pmc Back pain in seniors: the Back pain Outcomes using Longitudinal Data (BOLD) cohort baseline data
    Jeffrey G Jarvik
    Department of Radiology, University of Washington, 325 Ninth Ave, Box 359728, Seattle, WA 98104 2499, USA
    BMC Musculoskelet Disord 15:134. 2014
    ..Our goal was to describe how pain, function and health-related quality of life vary by demographic and geographic factors among seniors presenting to primary care providers with new episodes of care for back pain...
  48. doi request reprint A model for incorporating patient and stakeholder voices in a learning health care network: Washington State's Comparative Effectiveness Research Translation Network
    Emily Beth Devine
    Pharmaceutical Outcome Research and Policy Program, University of Washington, Seattle, WA, USA
    J Clin Epidemiol 66:S122-9. 2013
    ....
  49. ncbi request reprint Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Am J Manag Care 12:197-202. 2006
    ....
  50. ncbi request reprint Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma
    Jonathan D Campbell
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington 98195, USA
    Ann Allergy Asthma Immunol 101:474-81. 2008
    ..The National Asthma Education and Prevention Program put forth guidance on how to measure asthma control. This guidance is flexible regarding how the impairment component of control is assessed...
  51. doi request reprint Cardiovascular events associated with ipratropium bromide in COPD
    Sarika S Ogale
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
    Chest 137:13-9. 2010
    ..We sought to examine the association between ipratropium bromide use and the risk of cardiovascular events (CVEs)...
  52. pmc The impact of computerized provider order entry on medication errors in a multispecialty group practice
    Emily Beth Devine
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington 98195 7630, USA
    J Am Med Inform Assoc 17:78-84. 2010
    ..The objective was to evaluate the effect of a basic, ambulatory CPOE system on medication errors and associated ADEs...
  53. pmc The impact of e-prescribing on prescriber and staff time in ambulatory care clinics: a time motion study
    William Hollingworth
    Department of Radiology, University of Washington, 325 Ninth Avenue, Seattle, WA 98104 2499, USA
    J Am Med Inform Assoc 14:722-30. 2007
    ..4 minutes/hour; 0.0, 10.7 CI). E-prescribing was not associated with an increase in combined computer and writing time for prescribers. If carefully implemented, e-prescribing will not greatly disrupt workflow...
  54. doi request reprint Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity
    Bruce C M Wang
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, H375Q, Seattle, WA, 98195, USA
    Eur J Health Econ 15:253-63. 2014
    ..One-third of Americans are obese and an increasing number opt for bariatric surgery. This study estimates the cost-effectiveness of common bariatric surgical procedures from a healthcare system perspective...
  55. doi request reprint Asthma control, cost and race: results from a national survey
    Laura S Gold
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195 9455, USA
    J Asthma 50:783-90. 2013
    ....
  56. pmc Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Oncologist 18:760-7. 2013
    ..In discussing these concepts, we also touched upon the notion of whether cancer is special among health issues with regard to how evidence is generated and used. ..
  57. pmc Headache-related health resource utilisation in chronic and episodic migraine across six countries
    Joanna C Sanderson
    Pharmaceutical Outcomes Research and Policy Program PORPP, University of Washington, Seattle, Washington, USA
    J Neurol Neurosurg Psychiatry 84:1309-17. 2013
    ..To describe headache-related health resource usage in chronic and episodic migraine across six countries...
  58. pmc Cost-effectiveness and population outcomes of general population screening for hepatitis C
    Phillip O Coffin
    Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98104, USA
    Clin Infect Dis 54:1259-71. 2012
    ..Current US guidelines recommend limiting hepatitis C virus (HCV) screening to high-risk individuals, and 50%-75% of infected persons remain unaware of their status...
  59. pmc Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
    Jonathan D Campbell
    School of Pharmacy, University of Washington, Seattle, USA
    BMC Urol 9:18. 2009
    ..Our objective was to conduct a literature review and synthesis of published measures of treatment success for OAB with UUI interventions and to identify a treatment success outcome...
  60. ncbi request reprint Resource costs for asthma-related care among pediatric patients in managed care
    Karna Gendo
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Ann Allergy Asthma Immunol 91:251-7. 2003
    ..Understanding the relationship between total costs of asthma-related care and morbidity can assist in designing the most cost-effective asthma care strategies to improve patient outcomes and minimize total costs...
  61. ncbi request reprint Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA 98109, USA
    N Engl J Med 348:2092-102. 2003
    ..The National Emphysema Treatment Trial, a randomized clinical trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, included a prospective economic analysis...
  62. ncbi request reprint Updated evaluation of the cost-effectiveness of lung volume reduction surgery
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3 B232, Seattle, WA 98109, USA
    Chest 131:823-32. 2007
    ..We present an updated analysis of cost-effectiveness with 1-year additional follow-up data...
  63. ncbi request reprint A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 20:21-30. 2002
    ....
  64. pmc Cost-effectiveness of lung volume reduction surgery
    Scott D Ramsey
    Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Am Thorac Soc 5:406-11. 2008
    ....
  65. ncbi request reprint Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C
    S D Sullivan
    University of Washington, Seattle WA 98195, USA
    Am J Gastroenterol 99:1490-6. 2004
    ..However, the cost-effectiveness of peginterferon alpha-2a plus ribavirin in the U.S. setting has not been investigated...
  66. doi request reprint Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Clin Ther 35:414-24. 2013
    ..However, the economic impact of onabotulinumtoxinA treatment for UI due to NDO in the United States remains unknown...
  67. doi request reprint Economic costs of nonmedical use of prescription opioids
    Ryan N Hansen
    Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Clin J Pain 27:194-202. 2011
    ....
  68. pmc CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort
    Lisa M Bloudek
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    J Alzheimers Dis 24:599-607. 2011
    ..The NACC-UDS dataset is ongoing and this analysis may be improved if repeated when more data is available...
  69. ncbi request reprint Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma
    Sean D Sullivan
    Department of Pharmacy and Health Services, University of Washington, Seattle, Washington 98195 7630, USA
    J Allergy Clin Immunol 112:1229-36. 2003
    ....
  70. doi request reprint The impact of using different imputation methods for missing quality of life scores on the estimation of the cost-effectiveness of lung-volume-reduction surgery
    David K Blough
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Health Econ 18:91-101. 2009
    ..Owing to the effects of different imputation methods for missing quality of life data on the estimation of the ICER, we recommend use of a minimum of two imputation methods that always include multiple imputation...
  71. ncbi request reprint An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes
    Scott D Ramsey
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USAUniversity of Washington, Seattle, WA 98109, USA
    Pharmacoeconomics 26:329-39. 2008
    ..We estimated the cost effectiveness of atorvastatin as primary prevention against CV disease from the short-term and lifetime US payer perspectives...
  72. ncbi request reprint The timing of elective colectomy in diverticulitis: a decision analysis
    Leon Salem
    Department of Surgery, University of Washington, Seattle, WA 98195 6410, USA
    J Am Coll Surg 199:904-12. 2004
    ..We used decision and cost analysis to simulate the clinical and economic outcomes after recovery from an episode of nonsurgically treated diverticulitis to determine the preferable management strategy...
  73. ncbi request reprint The cost-effectiveness of an inner-city asthma intervention for children
    Sean D Sullivan
    Departments of Pharmacy and Health Services, Box 357630, University of Washington, Seattle, WA 98195, USA
    J Allergy Clin Immunol 110:576-81. 2002
    ..The National Cooperative Inner-City Asthma Study (NCICAS) demonstrated improved symptom outcomes but did not evaluate cost-effectiveness in this population...
  74. ncbi request reprint A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
    Med Decis Making 23:252-64. 2003
    ..Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations...
  75. pmc Cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding, and nonoperative weight loss interventions
    Leon Salem
    Department of Surgery, University of Washington School of Medicine, Seattle, Washington 98195 6410, USA
    Surg Obes Relat Dis 4:26-32. 2008
    ..We designed a model to evaluate the incremental cost-effectiveness of these procedures compared with nonoperative weight loss interventions and with each other...
  76. doi request reprint Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach
    Emily Beth Devine
    Pharmaceutical Outcomes Research and Policy Program, Department of Medical Education and Biomedical Informatics, University of Washington, Seattle, Washington 98195 7630, USA
    Pharmacotherapy 31:39-51. 2011
    ..To compare the efficacy of biologic disease-modifying antirheumatic drugs (DMARDs) versus placebo with or without methotrexate, in treating rheumatoid arthritis...
  77. pmc Prescriber and staff perceptions of an electronic prescribing system in primary care: a qualitative assessment
    Emily Beth Devine
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    BMC Med Inform Decis Mak 10:72. 2010
    ..We describe prescriber and staff perceptions of implementation of a CPOE system for medications (electronic- or e-prescribing system) in the ambulatory setting...
  78. ncbi request reprint Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference?
    Andy Stergachis
    Department of Pharmacy, University of Washington, Seattle 98105, USA
    J Am Pharm Assoc (Wash) 42:743-52. 2002
    ..To assess the effect of a structured program of pharmaceutical care on changes in disease control, functional status, and health services utilization for pediatric and adolescent patients with moderate-to-severe asthma...
  79. ncbi request reprint Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Manag Care 16:678-86. 2010
    ..To examine variables influencing colony-stimulating factor (CSF) prescription as primary prophylaxis versus other use during patients' initial chemotherapy course among a large sample of health insurance records...
  80. doi request reprint Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder
    Jonathan H Watanabe
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Urology 76:835-40. 2010
    ....
  81. ncbi request reprint Chronic obstructive pulmonary disease: is there a case for early intervention?
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Am J Med 117:3S-10S. 2004
    ..The economic value of aggressive pharmacotherapy for early-stage COPD is less certain, but the burden of illness and potential pharmacoeconomic benefits in such patients is a strong rationale for combined clinical and economic trials...
  82. ncbi request reprint Characterization of prescribing errors in an internal medicine clinic
    Emily Beth Devine
    Department of Pharmacy, University of Washington UW, Seattle, WA 98195 7630, USA
    Am J Health Syst Pharm 64:1062-70. 2007
    ....
  83. ncbi request reprint Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002
    Judy T Zerzan
    HSR and D Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA 98101, USA
    Med Care 44:1005-10. 2006
    ..This study describes temporal and interstate variability in aggregate prescription opiate medication use within U.S. Medicaid programs...
  84. ncbi request reprint Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction
    Teal S Hallstrand
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, The School of Public Health and Community Medicine, University of Washington, Seattle 98195, USA
    J Pediatr 141:343-8. 2002
    ....
  85. pmc Rapid magnetic resonance imaging for diagnosing cancer-related low back pain
    William Hollingworth
    Departments of Radiology, University of Washington, Seattle, Wash 98103, USA
    J Gen Intern Med 18:303-12. 2003
    ..This study compared the relative efficiency of lumbar x-ray and rapid magnetic resonance (MR) imaging for diagnosing cancer-related low back pain (LBP) in primary care patients...
  86. ncbi request reprint Health care utilization and cost among adults with chronic rhinosinusitis enrolled in a health maintenance organization
    Michael P Murphy
    Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, Washington, USA
    Otolaryngol Head Neck Surg 127:367-76. 2002
    ..Outcome Measures: We identified nonurgent outpatient visits, pharmacy fills, urgent visits, hospital days, and their associated costs (per adult per year)...
  87. ncbi request reprint Collaborative care model to improve outcomes in major depression
    Denise M Boudreau
    Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Ann Pharmacother 36:585-91. 2002
    ..To develop a pharmacist intervention to improve depression care and outcomes within a primary care setting...
  88. ncbi request reprint More isn't always better: cost-effectiveness analysis and the case for using a split-night protocol
    Vishesh K Kapur
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Clin Sleep Med 2:154-5. 2006
  89. ncbi request reprint Development of a quantifiable symptom assessment tool for patients with chronic bronchitis: the Chronic Bronchitis Symptoms Assessment Scale
    David H Au
    Health Services Research and Development, VA Puget Sound Health Care System, 1660 S Columbian Way, Seattle, Washington 98108, USA
    COPD 2:209-16. 2005
    ..67) and SOBQ (r = 0.50). The Chronic Bronchitis Symptoms Assessment Scale is an easy to administer, once daily or once weekly, valid and reliable outcome measure for assessing symptom severity among patients with chronic bronchitis...
  90. ncbi request reprint Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS
    T A Lee
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle 98195, USA
    Pharmacoeconomics 19:535-50. 2001
    ..To determine the cost of using systemic therapy to treat newly diagnosed cytomegalovirus (CMV) retinitis in persons with AIDS...
  91. ncbi request reprint Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications
    E B Devine
    University of Washington, Department of Pharmacy, Box 357630, Seattle, WA 98195 7630, USA
    Value Health 4:376-84. 2001
    ..The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting...
  92. pmc Modeling the cost and outcomes of pharmacist-prescribed emergency contraception
    K D Marciante
    Department of Pharmacy, University of Washington, Seattle, 98195, USA
    Am J Public Health 91:1443-5. 2001
    ..This study investigated the effect on the risk and cost of unintended pregnancies of emergency contraceptive pills obtained directly from a pharmacist...
  93. ncbi request reprint Cost and cost-effectiveness of universal screening for hearing loss in newborns
    E J Kezirian
    Department of Otolaryngology Head and Neck Surgery, University of Washington, Seattle, 98195, USA
    Otolaryngol Head Neck Surg 124:359-67. 2001
    ..To estimate the cost and cost-effectiveness of universal newborn hearing screening...
  94. ncbi request reprint The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin
    E B Devine
    University of Washington Department of Pharmacy, Seattle, WA 98195 7630, USA
    Curr Med Res Opin 23:1463-72. 2007
    ..The secondary objective was to calculate the incremental cost of using epoetin versus no epoetin to treat RIA, per ribavirin dose reduction/discontinuation averted...
  95. ncbi request reprint The costs of treating COPD in the United States
    S A Strassels
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Chest 119:344-52. 2001
    ..COPD affects millions of people in the United States. The purpose of this study was to describe the medical resource use and costs incurred by persons with COPD in the United States in 1987...
  96. ncbi request reprint Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program and Department of Pharmacy, University of Washington, Seattle 98195 7630, USA
    JAMA 282:554-60. 1999
    ....
  97. ncbi request reprint The economics of treatment for infants with respiratory distress syndrome
    N Neil
    Department of Pharmacy, University of Washington, Seattle 98195 8773, USA
    Med Decis Making 18:44-51. 1998
    ....
  98. ncbi request reprint Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis
    D L Veenstra
    Department of Pharmacy, University of Washington, Seattle, USA
    JAMA 281:261-7. 1999
    ..However, there remains some uncertainty regarding the efficacy of these catheters because of conflicting reports in the literature...
  99. doi request reprint The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
    J D Campbell
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, H375Q, Box 357630, Seattle, WA 98195, USA
    Eur Respir J 32:1237-42. 2008
    ..While additional studies are needed, the present findings call for alternative therapeutic approaches in severe/difficult-to-treat asthma for those unable to attain asthma control with or without salmeterol/fluticasone combination...
  100. doi request reprint Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
    ..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
  101. ncbi request reprint States' control of prescription drug spending: a heterogeneous approach
    Nancy E Morden
    University of Washington, in Seattle, USA
    Health Aff (Millwood) 24:1032-8. 2005
    ....